nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—SLC6A4—chronic obstructive pulmonary disease	0.522	1	CbGaD
Vilazodone—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0512	0.17	CbGbCtD
Vilazodone—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0512	0.17	CbGbCtD
Vilazodone—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0456	0.152	CbGbCtD
Vilazodone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0429	0.143	CbGbCtD
Vilazodone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.029	0.0966	CbGbCtD
Vilazodone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0277	0.0921	CbGbCtD
Vilazodone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0247	0.0821	CbGbCtD
Vilazodone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0145	0.0482	CbGbCtD
Vilazodone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0137	0.0455	CbGbCtD
Vilazodone—Angle closure glaucoma—Tiotropium—chronic obstructive pulmonary disease	0.00576	0.044	CcSEcCtD
Vilazodone—Haemorrhagic disorder—Montelukast—chronic obstructive pulmonary disease	0.00486	0.0371	CcSEcCtD
Vilazodone—Completed suicide—Roflumilast—chronic obstructive pulmonary disease	0.0042	0.0321	CcSEcCtD
Vilazodone—Suicidal ideation—Roflumilast—chronic obstructive pulmonary disease	0.00352	0.0269	CcSEcCtD
Vilazodone—Suicide—Montelukast—chronic obstructive pulmonary disease	0.00237	0.0181	CcSEcCtD
Vilazodone—Suicide attempt—Montelukast—chronic obstructive pulmonary disease	0.00216	0.0165	CcSEcCtD
Vilazodone—Completed suicide—Montelukast—chronic obstructive pulmonary disease	0.00209	0.0159	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Aminophylline—chronic obstructive pulmonary disease	0.00182	0.0139	CcSEcCtD
Vilazodone—Cataract—Tiotropium—chronic obstructive pulmonary disease	0.00163	0.0125	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Arformoterol—chronic obstructive pulmonary disease	0.00139	0.0106	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Formoterol—chronic obstructive pulmonary disease	0.00139	0.0106	CcSEcCtD
Vilazodone—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.00122	0.00931	CcSEcCtD
Vilazodone—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00115	0.00879	CcSEcCtD
Vilazodone—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.00114	0.00872	CcSEcCtD
Vilazodone—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.00109	0.0083	CcSEcCtD
Vilazodone—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00108	0.00825	CcSEcCtD
Vilazodone—Dysgeusia—Roflumilast—chronic obstructive pulmonary disease	0.00106	0.00807	CcSEcCtD
Vilazodone—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.00105	0.00801	CcSEcCtD
Vilazodone—Gastroenteritis—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00784	CcSEcCtD
Vilazodone—Gastroenteritis—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00784	CcSEcCtD
Vilazodone—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.00101	0.00773	CcSEcCtD
Vilazodone—Gastroenteritis—Montelukast—chronic obstructive pulmonary disease	0.00101	0.00768	CcSEcCtD
Vilazodone—Gastroenteritis—Salbutamol—chronic obstructive pulmonary disease	0.000969	0.0074	CcSEcCtD
Vilazodone—Palpitations—Roflumilast—chronic obstructive pulmonary disease	0.000954	0.00729	CcSEcCtD
Vilazodone—Increased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000914	0.00698	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000912	0.00697	CcSEcCtD
Vilazodone—Aripiprazole—SLC6A4—chronic obstructive pulmonary disease	0.000875	0.283	CrCbGaD
Vilazodone—Trazodone—SLC6A4—chronic obstructive pulmonary disease	0.000871	0.282	CrCbGaD
Vilazodone—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.000864	0.0066	CcSEcCtD
Vilazodone—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000855	0.00654	CcSEcCtD
Vilazodone—Irritability—Montelukast—chronic obstructive pulmonary disease	0.00085	0.0065	CcSEcCtD
Vilazodone—Migraine—Salbutamol—chronic obstructive pulmonary disease	0.000845	0.00646	CcSEcCtD
Vilazodone—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.00082	0.00626	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000802	0.00613	CcSEcCtD
Vilazodone—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.000797	0.00609	CcSEcCtD
Vilazodone—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.000775	0.00592	CcSEcCtD
Vilazodone—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.000766	0.00585	CcSEcCtD
Vilazodone—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.000766	0.00585	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00076	0.00581	CcSEcCtD
Vilazodone—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000759	0.0058	CcSEcCtD
Vilazodone—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.000729	0.00557	CcSEcCtD
Vilazodone—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.000726	0.00555	CcSEcCtD
Vilazodone—Suicidal ideation—Prednisone—chronic obstructive pulmonary disease	0.000703	0.00537	CcSEcCtD
Vilazodone—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000699	0.00534	CcSEcCtD
Vilazodone—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.000683	0.00522	CcSEcCtD
Vilazodone—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000679	0.00519	CcSEcCtD
Vilazodone—Mania—Prednisone—chronic obstructive pulmonary disease	0.000678	0.00518	CcSEcCtD
Vilazodone—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000674	0.00515	CcSEcCtD
Vilazodone—Aripiprazole—HTR2A—chronic obstructive pulmonary disease	0.000673	0.218	CrCbGaD
Vilazodone—Trazodone—HTR2A—chronic obstructive pulmonary disease	0.00067	0.217	CrCbGaD
Vilazodone—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000661	0.00505	CcSEcCtD
Vilazodone—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00064	0.00489	CcSEcCtD
Vilazodone—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.000636	0.00486	CcSEcCtD
Vilazodone—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000632	0.00483	CcSEcCtD
Vilazodone—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000624	0.00476	CcSEcCtD
Vilazodone—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000618	0.00472	CcSEcCtD
Vilazodone—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000618	0.00472	CcSEcCtD
Vilazodone—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000613	0.00469	CcSEcCtD
Vilazodone—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000606	0.00463	CcSEcCtD
Vilazodone—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000603	0.0046	CcSEcCtD
Vilazodone—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.0006	0.00458	CcSEcCtD
Vilazodone—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000584	0.00446	CcSEcCtD
Vilazodone—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000584	0.00446	CcSEcCtD
Vilazodone—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000584	0.00446	CcSEcCtD
Vilazodone—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000582	0.00445	CcSEcCtD
Vilazodone—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000578	0.00441	CcSEcCtD
Vilazodone—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000576	0.0044	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000574	0.00438	CcSEcCtD
Vilazodone—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000572	0.00437	CcSEcCtD
Vilazodone—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000565	0.00432	CcSEcCtD
Vilazodone—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00056	0.00428	CcSEcCtD
Vilazodone—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000551	0.00421	CcSEcCtD
Vilazodone—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000551	0.00421	CcSEcCtD
Vilazodone—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000551	0.00421	CcSEcCtD
Vilazodone—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000548	0.00419	CcSEcCtD
Vilazodone—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000548	0.00419	CcSEcCtD
Vilazodone—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000543	0.00415	CcSEcCtD
Vilazodone—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00054	0.00413	CcSEcCtD
Vilazodone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000538	0.00411	CcSEcCtD
Vilazodone—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000536	0.0041	CcSEcCtD
Vilazodone—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000536	0.0041	CcSEcCtD
Vilazodone—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000532	0.00406	CcSEcCtD
Vilazodone—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000532	0.00406	CcSEcCtD
Vilazodone—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000531	0.00406	CcSEcCtD
Vilazodone—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000524	0.00401	CcSEcCtD
Vilazodone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000523	0.004	CcSEcCtD
Vilazodone—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00052	0.00398	CcSEcCtD
Vilazodone—Cataract—Prednisone—chronic obstructive pulmonary disease	0.000518	0.00396	CcSEcCtD
Vilazodone—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000517	0.00395	CcSEcCtD
Vilazodone—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000517	0.00395	CcSEcCtD
Vilazodone—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000513	0.00392	CcSEcCtD
Vilazodone—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000513	0.00392	CcSEcCtD
Vilazodone—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000511	0.0039	CcSEcCtD
Vilazodone—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00051	0.00389	CcSEcCtD
Vilazodone—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000506	0.00387	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000505	0.00386	CcSEcCtD
Vilazodone—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000503	0.00385	CcSEcCtD
Vilazodone—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000503	0.00385	CcSEcCtD
Vilazodone—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000503	0.00384	CcSEcCtD
Vilazodone—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000502	0.00384	CcSEcCtD
Vilazodone—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000501	0.00383	CcSEcCtD
Vilazodone—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000497	0.0038	CcSEcCtD
Vilazodone—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000493	0.00377	CcSEcCtD
Vilazodone—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000488	0.00373	CcSEcCtD
Vilazodone—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000485	0.0037	CcSEcCtD
Vilazodone—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000484	0.0037	CcSEcCtD
Vilazodone—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000484	0.0037	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000478	0.00365	CcSEcCtD
Vilazodone—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00363	CcSEcCtD
Vilazodone—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000474	0.00362	CcSEcCtD
Vilazodone—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000466	0.00356	CcSEcCtD
Vilazodone—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000466	0.00356	CcSEcCtD
Vilazodone—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000465	0.00355	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000463	0.00354	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000463	0.00354	CcSEcCtD
Vilazodone—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000457	0.00349	CcSEcCtD
Vilazodone—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000457	0.00349	CcSEcCtD
Vilazodone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000456	0.00348	CcSEcCtD
Vilazodone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000456	0.00348	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000454	0.00347	CcSEcCtD
Vilazodone—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00044	0.00336	CcSEcCtD
Vilazodone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000438	0.00335	CcSEcCtD
Vilazodone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.00335	CcSEcCtD
Vilazodone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000434	0.00332	CcSEcCtD
Vilazodone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000434	0.00332	CcSEcCtD
Vilazodone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000431	0.00329	CcSEcCtD
Vilazodone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000429	0.00328	CcSEcCtD
Vilazodone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000425	0.00325	CcSEcCtD
Vilazodone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000414	0.00316	CcSEcCtD
Vilazodone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00041	0.00313	CcSEcCtD
Vilazodone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000408	0.00312	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000407	0.00311	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000407	0.00311	CcSEcCtD
Vilazodone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000404	0.00309	CcSEcCtD
Vilazodone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000404	0.00309	CcSEcCtD
Vilazodone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000402	0.00307	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00305	CcSEcCtD
Vilazodone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000397	0.00304	CcSEcCtD
Vilazodone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000397	0.00304	CcSEcCtD
Vilazodone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000396	0.00303	CcSEcCtD
Vilazodone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00301	CcSEcCtD
Vilazodone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00301	CcSEcCtD
Vilazodone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000393	0.003	CcSEcCtD
Vilazodone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000389	0.00297	CcSEcCtD
Vilazodone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000388	0.00297	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000386	0.00295	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000386	0.00295	CcSEcCtD
Vilazodone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00294	CcSEcCtD
Vilazodone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000385	0.00294	CcSEcCtD
Vilazodone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.00294	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000385	0.00294	CcSEcCtD
Vilazodone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000382	0.00292	CcSEcCtD
Vilazodone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000381	0.00291	CcSEcCtD
Vilazodone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000379	0.0029	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000378	0.00289	CcSEcCtD
Vilazodone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000377	0.00288	CcSEcCtD
Vilazodone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.00287	CcSEcCtD
Vilazodone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000373	0.00285	CcSEcCtD
Vilazodone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000372	0.00284	CcSEcCtD
Vilazodone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000368	0.00281	CcSEcCtD
Vilazodone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000368	0.00281	CcSEcCtD
Vilazodone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.0028	CcSEcCtD
Vilazodone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000366	0.0028	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00278	CcSEcCtD
Vilazodone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00278	CcSEcCtD
Vilazodone—CYP2C18—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000354	0.00813	CbGpPWpGaD
Vilazodone—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000353	0.00811	CbGpPWpGaD
Vilazodone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000352	0.00269	CcSEcCtD
Vilazodone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000349	0.00267	CcSEcCtD
Vilazodone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00266	CcSEcCtD
Vilazodone—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000342	0.00261	CcSEcCtD
Vilazodone—DRD2—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000341	0.00782	CbGpPWpGaD
Vilazodone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000329	0.00251	CcSEcCtD
Vilazodone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000321	0.00245	CcSEcCtD
Vilazodone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000321	0.00245	CcSEcCtD
Vilazodone—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000318	0.0073	CbGpPWpGaD
Vilazodone—DRD2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000317	0.00727	CbGpPWpGaD
Vilazodone—SLC6A4—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000315	0.00722	CbGpPWpGaD
Vilazodone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000314	0.0024	CcSEcCtD
Vilazodone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000306	0.00234	CcSEcCtD
Vilazodone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000306	0.00234	CcSEcCtD
Vilazodone—HTR1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000303	0.00696	CbGpPWpGaD
Vilazodone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.00231	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000302	0.00694	CbGpPWpGaD
Vilazodone—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000302	0.00693	CbGpPWpGaD
Vilazodone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.0003	0.00229	CcSEcCtD
Vilazodone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000296	0.00226	CcSEcCtD
Vilazodone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.00226	CcSEcCtD
Vilazodone—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000296	0.00678	CbGpPWpGaD
Vilazodone—CYP2C18—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000291	0.00668	CbGpPWpGaD
Vilazodone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00029	0.00221	CcSEcCtD
Vilazodone—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000289	0.00664	CbGpPWpGaD
Vilazodone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000289	0.00221	CcSEcCtD
Vilazodone—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000285	0.00218	CcSEcCtD
Vilazodone—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000284	0.00652	CbGpPWpGaD
Vilazodone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000284	0.00217	CcSEcCtD
Vilazodone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000284	0.00217	CcSEcCtD
Vilazodone—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00028	0.00214	CcSEcCtD
Vilazodone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000279	0.00213	CcSEcCtD
Vilazodone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000278	0.00213	CcSEcCtD
Vilazodone—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000277	0.00636	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000276	0.00634	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.00027	0.0062	CbGpPWpGaD
Vilazodone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000268	0.00205	CcSEcCtD
Vilazodone—DRD2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000266	0.00611	CbGpPWpGaD
Vilazodone—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000266	0.0061	CbGpPWpGaD
Vilazodone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.00203	CcSEcCtD
Vilazodone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000266	0.00203	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000262	0.00601	CbGpPWpGaD
Vilazodone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00026	0.00199	CcSEcCtD
Vilazodone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000257	0.00196	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000256	0.00588	CbGpPWpGaD
Vilazodone—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000256	0.00587	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000253	0.00581	CbGpPWpGaD
Vilazodone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00192	CcSEcCtD
Vilazodone—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000246	0.00188	CcSEcCtD
Vilazodone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000243	0.00186	CcSEcCtD
Vilazodone—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000234	0.00538	CbGpPWpGaD
Vilazodone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000234	0.00179	CcSEcCtD
Vilazodone—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000231	0.00177	CcSEcCtD
Vilazodone—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000231	0.0053	CbGpPWpGaD
Vilazodone—SLC6A4—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000228	0.00524	CbGpPWpGaD
Vilazodone—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000222	0.00509	CbGpPWpGaD
Vilazodone—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.00022	0.00504	CbGpPWpGaD
Vilazodone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00167	CcSEcCtD
Vilazodone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00166	CcSEcCtD
Vilazodone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000217	0.00166	CcSEcCtD
Vilazodone—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00165	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000213	0.00488	CbGpPWpGaD
Vilazodone—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00021	0.00482	CbGpPWpGaD
Vilazodone—CYP2C18—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00021	0.00482	CbGpPWpGaD
Vilazodone—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000203	0.00155	CcSEcCtD
Vilazodone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000199	0.00152	CcSEcCtD
Vilazodone—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000198	0.00151	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000194	0.00445	CbGpPWpGaD
Vilazodone—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000193	0.00443	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000191	0.00439	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000188	0.00432	CbGpPWpGaD
Vilazodone—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000187	0.00143	CcSEcCtD
Vilazodone—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000186	0.00426	CbGpPWpGaD
Vilazodone—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000184	0.0014	CcSEcCtD
Vilazodone—SLC6A4—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000183	0.00419	CbGpPWpGaD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000182	0.00139	CcSEcCtD
Vilazodone—SLC6A4—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000182	0.00418	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000178	0.00409	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000178	0.00407	CbGpPWpGaD
Vilazodone—CYP2C18—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000175	0.00402	CbGpPWpGaD
Vilazodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000174	0.00399	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000173	0.00396	CbGpPWpGaD
Vilazodone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00132	CcSEcCtD
Vilazodone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000171	0.00131	CcSEcCtD
Vilazodone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00017	0.0013	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.00017	0.0039	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000169	0.00388	CbGpPWpGaD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000169	0.00388	CbGpPWpGaD
Vilazodone—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000167	0.00383	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000163	0.00374	CbGpPWpGaD
Vilazodone—CYP2C18—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000161	0.00369	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00122	CcSEcCtD
Vilazodone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00122	CcSEcCtD
Vilazodone—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00122	CcSEcCtD
Vilazodone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000158	0.00121	CcSEcCtD
Vilazodone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000155	0.00118	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000155	0.00355	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000153	0.00351	CbGpPWpGaD
Vilazodone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00117	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000153	0.0035	CbGpPWpGaD
Vilazodone—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00116	CcSEcCtD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.00015	0.00343	CbGpPWpGaD
Vilazodone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000145	0.00111	CcSEcCtD
Vilazodone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.0011	CcSEcCtD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000142	0.00326	CbGpPWpGaD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000137	0.00314	CbGpPWpGaD
Vilazodone—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000137	0.00313	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000134	0.00308	CbGpPWpGaD
Vilazodone—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000964	CcSEcCtD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000125	0.00286	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—APIP—chronic obstructive pulmonary disease	0.000124	0.00286	CbGpPWpGaD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000123	0.00282	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000122	0.00279	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000122	0.00279	CbGpPWpGaD
Vilazodone—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000121	0.00278	CbGpPWpGaD
Vilazodone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00092	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000118	0.0027	CbGpPWpGaD
Vilazodone—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000889	CcSEcCtD
Vilazodone—SLC6A4—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000113	0.0026	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000113	0.00259	CbGpPWpGaD
Vilazodone—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000855	CcSEcCtD
Vilazodone—DRD2—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000112	0.00256	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000111	0.00255	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00011	0.00253	CbGpPWpGaD
Vilazodone—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.0025	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000107	0.00245	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000106	0.00243	CbGpPWpGaD
Vilazodone—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000798	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000104	0.00239	CbGpPWpGaD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.95e-05	0.00228	CbGpPWpGaD
Vilazodone—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.93e-05	0.00228	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	9.27e-05	0.00213	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	9.24e-05	0.00212	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	8.95e-05	0.00205	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	8.91e-05	0.00204	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	8.91e-05	0.00204	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	8.86e-05	0.00203	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.75e-05	0.00201	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.65e-05	0.00199	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.24e-05	0.00189	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	8.14e-05	0.00187	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.02e-05	0.00184	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GC—chronic obstructive pulmonary disease	8.02e-05	0.00184	CbGpPWpGaD
Vilazodone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.92e-05	0.00182	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	7.82e-05	0.0018	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	7.63e-05	0.00175	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.59e-05	0.00174	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	7.5e-05	0.00172	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.45e-05	0.00171	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.27e-05	0.00167	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	7.26e-05	0.00167	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.17e-05	0.00165	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.97e-05	0.0016	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	6.94e-05	0.00159	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	6.82e-05	0.00157	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	6.7e-05	0.00154	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	6.66e-05	0.00153	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.51e-05	0.00149	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	6.5e-05	0.00149	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	6.47e-05	0.00148	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	6.44e-05	0.00148	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	6.43e-05	0.00148	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	6.17e-05	0.00142	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.12e-05	0.0014	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.07e-05	0.00139	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	5.99e-05	0.00137	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.98e-05	0.00137	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.97e-05	0.00137	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.9e-05	0.00135	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.81e-05	0.00133	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.72e-05	0.00131	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.7e-05	0.00131	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.66e-05	0.0013	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.58e-05	0.00128	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.5e-05	0.00126	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	5.45e-05	0.00125	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.29e-05	0.00121	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.24e-05	0.0012	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.24e-05	0.0012	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	5.23e-05	0.0012	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.21e-05	0.0012	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.19e-05	0.00119	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	5.19e-05	0.00119	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.18e-05	0.00119	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.1e-05	0.00117	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.76e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.76e-05	0.00109	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.69e-05	0.00108	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.64e-05	0.00106	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	4.63e-05	0.00106	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.6e-05	0.00106	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.6e-05	0.00106	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.56e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.54e-05	0.00104	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.48e-05	0.00103	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.38e-05	0.00101	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GCLC—chronic obstructive pulmonary disease	4.33e-05	0.000994	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	4.25e-05	0.000976	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	4.24e-05	0.000972	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.18e-05	0.000958	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.07e-05	0.000934	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.04e-05	0.000927	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.99e-05	0.000916	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.97e-05	0.00091	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CTGF—chronic obstructive pulmonary disease	3.95e-05	0.000907	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.91e-05	0.000898	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.69e-05	0.000846	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.65e-05	0.000836	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.64e-05	0.000835	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.62e-05	0.00083	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.6e-05	0.000825	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.49e-05	0.0008	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.46e-05	0.000793	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.41e-05	0.000782	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.29e-05	0.000754	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.24e-05	0.000743	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.06e-05	0.000702	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.04e-05	0.000697	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.99e-05	0.000687	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.98e-05	0.000685	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.94e-05	0.000674	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.88e-05	0.000662	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.83e-05	0.00065	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.82e-05	0.000646	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.81e-05	0.000645	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.81e-05	0.000644	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.79e-05	0.00064	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.78e-05	0.000638	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.74e-05	0.000629	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.67e-05	0.000612	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.65e-05	0.000607	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.62e-05	0.000601	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.59e-05	0.000595	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.58e-05	0.000591	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.57e-05	0.000589	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.55e-05	0.000585	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.47e-05	0.000566	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.47e-05	0.000566	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.34e-05	0.000537	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.33e-05	0.000535	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.25e-05	0.000517	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.05e-05	0.000471	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.05e-05	0.00047	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.91e-05	0.000438	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.84e-05	0.000423	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.8e-05	0.000414	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALB—chronic obstructive pulmonary disease	1.8e-05	0.000413	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.79e-05	0.000411	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.76e-05	0.000404	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NOS3—chronic obstructive pulmonary disease	1.72e-05	0.000395	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.68e-05	0.000385	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.67e-05	0.000382	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.59e-05	0.000364	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.57e-05	0.000361	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.55e-05	0.000355	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.5e-05	0.000343	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.48e-05	0.00034	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.44e-05	0.000331	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.43e-05	0.000328	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.39e-05	0.00032	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.38e-05	0.000317	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.38e-05	0.000316	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.35e-05	0.00031	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.28e-05	0.000294	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.27e-05	0.00029	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.26e-05	0.000288	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.24e-05	0.000285	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.21e-05	0.000278	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.12e-05	0.000258	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.05e-05	0.000242	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.04e-05	0.000238	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.02e-05	0.000235	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.01e-05	0.000231	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.79e-06	0.000225	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	9.67e-06	0.000222	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.6e-06	0.00022	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.53e-06	0.000219	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.25e-06	0.000212	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.04e-06	0.000207	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.83e-06	0.000203	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.82e-06	0.000202	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.51e-06	0.000195	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.42e-06	0.000193	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.13e-06	0.000187	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.09e-06	0.000186	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.7e-06	0.000177	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.47e-06	0.000171	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.11e-06	0.000163	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.91e-06	0.000159	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.78e-06	0.000156	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.76e-06	0.000155	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.69e-06	0.000154	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.34e-06	0.000146	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.23e-06	0.000143	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.22e-06	0.000143	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	6.14e-06	0.000141	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.07e-06	0.000139	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.91e-06	0.000136	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.88e-06	0.000135	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.57e-06	0.000128	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.46e-06	0.000125	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.22e-06	0.00012	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.78e-06	0.00011	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.59e-06	0.000105	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.2e-06	9.63e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.02e-06	9.22e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.84e-06	8.82e-05	CbGpPWpGaD
